In Vitro Activity of Ceftaroline Against Gram-Positive and Gram-Negative Pathogens Isolated From Patients Attending Canadian Hospitals in 2009.
Antimicrob Agents Chemother. 2011 Mar 14;
Authors: Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG
The in vitro activities of ceftaroline and comparative agents were determined for a collection of the most frequent bacterial pathogens isolated from hospital-associated patients across Canada in 2009 as part of the ongoing CANWARD surveillance study. In total, 4546 isolates from 15 sentinel Canadian hospital laboratories were tested using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Compared with other cephalosporins, including ceftobiprole, cefepime, and ceftriaxone, ceftaroline exhibited the greatest potency against methicillin-susceptible Staphylococcus aureus (MSSA), inhibiting 90% of the isolates tested (MIC90) at a concentration of 0.25 ?g/ml. Ceftaroline also demonstrated greater potency than ceftobiprole against community-associated methicillin-resistant S. aureus (MRSA; MIC90, 0.5 ?g/ml) and healthcare-associated MRSA (MIC90, 1 ?g/ml), and was at least four-fold more active than other cephalosporins against Staphylococcus epidermidis; all isolates of MSSA and MRSA tested were susceptible to ceftaroline (MIC, ?1 ?g/ml). Against streptococci, including Streptococcus pneumoniae, ceftaroline MICs (MIC90, ?0.03 ?g/ml) were comparable to those of ceftobiprole; however, against penicillin non-susceptible and macrolide non-susceptible, and multidrug non-susceptible isolates of S. pneumoniae, ceftaroline demonstrated two- to four-fold, and four- to 16-fold, respectively, more potent activity than ceftobiprole and ceftriaxone. All isolates of S. pneumoniae tested were susceptible to ceftaroline (MIC, ?0.25 ?g/ml). Against gram-negative isolates, ceftaroline demonstrated potent activity (MIC90, ?0.5 ?g/ml) against Escherichia coli (92.2% susceptible), Klebsiella pneumoniae (94.1% susceptible), Proteus mirabilis (97.7% susceptible), and Haemophilus influenzae (100% susceptible). Ceftaroline demonstrated less potent activity (MIC90, ?4 ?g/ml) against Enterobacter spp., Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella oxytoca, Serratia marcescens, and Stenotrophomonas maltophilia. Overall, ceftaroline demonstrated potent in vitro activity against a recent collection of the most frequently encountered gram-positive and gram-negative isolates from patients attending hospitals across Canada in 2009.
PMID: 21402844 [PubMed - as supplied by publisher]